U.S.S.N. 10/086,398 FILED FEBRUARY 28, 2002 AMENDMENT

## In the Claims

## Claim 1-22 previously canceled.

- 23. (Previously presented) A composition for decreasing the production of Aβ comprising an effective amount of a compound decreasing blood cholesterol levels to decrease Aβ production by neuronal cells in an individual at risk of developing Alzheimer's dosage formulation comprising a pharmaceutically acceptable carrier for administration to neurons and a cholesterol lowering compound which crosses the blood brain barrier, wherein the dosage formulation provides an effective amount of the cholesterol lowering compound to decrease Aβ production in the neurons.
- 24. (Previously presented) The eomposition formulation of claim 23 wherein the cholesterol-lowering compound comprises comprising an HMG CoA Reductase inhibitor
- 25. (Previously presented) The composition formulation of claim 24 wherein the inhibitor is selected from the group consisting of lovastatin, simvastatin, fluvastatin, pravastatin, Atorvastatin, cerivastatin, and compactin.
- 26. (Previously presented) The composition formulation of claim 23 comprising a compound which inhibits uptake of dietary cholesterol.
- 27. (Previously presented) The empesition formulation of claim 23 wherein the empesition cholesterol-lowering compound blocks or decreases endogenous cholesterol production.

U.S.S.N. 10/086,398 FILED FEBRUARY 28, 2002 AMENDMENT

- 28. (Previously presented) The eomposition formulation of claim 27 wherein the eomposition cholesterol-lowering compound comprises an inhibitor of the cholesterol biosynthetic enzymes selected from the group consisting of 2,3-oxidosqualene cyclase, Squalene synthase, and 7-dehydrocholesterol reductase.
- 29. (Previously presented) The composition formulation of claim 23 wherein the composition cholesterol-lowering compound is selected from the group consisting of a fibrate, a bile acid binding resin, probucol, nicotinic acid, garlic or garlic derivative, and psyllium.